Celgene Wants Barr's Antitrust Claims Put On Hold

Law360, New York (November 5, 2007, 12:00 AM EST) -- Celgene Corp. is asking a New Jersey court to put the antitrust and unfair competition counterclaims Barr Laboratories Inc. lodged in response to Celgene's patent infringement complaint over the cancer drug Thalomid on the back burner, arguing that letting the counterclaims go forward now would waste the court's time.

On Friday, Celgene filed its motion to bifurcate and stay discovery of Barr's antitrust and unfair competition counterclaims, which Barr filed on Oct. 10 when it answered Celgene's amended complaint, which asserted eight Thalomid patents against Barr....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.